ICU Medical (NASDAQ:ICUI) Upgraded at StockNews.com

StockNews.com upgraded shares of ICU Medical (NASDAQ:ICUI) from a hold rating to a buy rating in a report published on Wednesday morning.

Several other brokerages also recently issued reports on ICUI. KeyCorp upped their target price on shares of ICU Medical from $198.00 to $209.00 and gave the stock an “overweight” rating in a research note on Wednesday, November 13th. Raymond James upped their price objective on ICU Medical from $158.00 to $190.00 and gave the company an “outperform” rating in a research report on Thursday, September 12th. Needham & Company LLC reissued a “hold” rating on shares of ICU Medical in a report on Wednesday, November 13th. Finally, Jefferies Financial Group began coverage on ICU Medical in a research note on Monday, October 14th. They issued a “hold” rating and a $183.00 price target for the company. Two investment analysts have rated the stock with a hold rating and four have assigned a buy rating to the company’s stock. Based on data from MarketBeat.com, the stock has a consensus rating of “Moderate Buy” and a consensus price target of $173.00.

ICU Medical Trading Down 1.2 %

Shares of ICU Medical stock opened at $167.59 on Wednesday. ICU Medical has a 1 year low of $82.82 and a 1 year high of $196.26. The firm’s 50-day moving average is $176.54 and its 200 day moving average is $144.46. The company has a current ratio of 2.29, a quick ratio of 1.03 and a debt-to-equity ratio of 0.75.

Insider Buying and Selling

In other news, CEO Vivek Jain sold 12,000 shares of the company’s stock in a transaction dated Tuesday, September 3rd. The shares were sold at an average price of $163.46, for a total transaction of $1,961,520.00. Following the completion of the sale, the chief executive officer now owns 104,593 shares of the company’s stock, valued at $17,096,771.78. This represents a 10.29 % decrease in their position. The transaction was disclosed in a document filed with the Securities & Exchange Commission, which is available through this link. Also, VP Daniel Woolson sold 2,502 shares of the firm’s stock in a transaction that occurred on Friday, August 30th. The stock was sold at an average price of $163.22, for a total transaction of $408,376.44. Following the completion of the transaction, the vice president now directly owns 13,107 shares in the company, valued at approximately $2,139,324.54. The trade was a 16.03 % decrease in their position. The disclosure for this sale can be found here. Over the last quarter, insiders have sold 38,502 shares of company stock worth $6,573,496. 6.70% of the stock is owned by insiders.

Institutional Inflows and Outflows

Institutional investors and hedge funds have recently modified their holdings of the business. Vanguard Group Inc. increased its stake in shares of ICU Medical by 0.5% in the 1st quarter. Vanguard Group Inc. now owns 2,452,720 shares of the medical instruments supplier’s stock worth $263,226,000 after purchasing an additional 11,991 shares in the last quarter. State Street Corp increased its position in ICU Medical by 9.3% in the third quarter. State Street Corp now owns 907,607 shares of the medical instruments supplier’s stock worth $165,384,000 after buying an additional 77,506 shares in the last quarter. Geode Capital Management LLC raised its stake in shares of ICU Medical by 9.6% in the third quarter. Geode Capital Management LLC now owns 546,954 shares of the medical instruments supplier’s stock worth $99,687,000 after buying an additional 48,106 shares during the period. Dimensional Fund Advisors LP lifted its position in shares of ICU Medical by 21.7% during the 2nd quarter. Dimensional Fund Advisors LP now owns 311,542 shares of the medical instruments supplier’s stock valued at $36,996,000 after buying an additional 55,588 shares in the last quarter. Finally, Charles Schwab Investment Management Inc. grew its stake in shares of ICU Medical by 10.2% during the 3rd quarter. Charles Schwab Investment Management Inc. now owns 301,107 shares of the medical instruments supplier’s stock valued at $54,868,000 after acquiring an additional 27,927 shares during the period. Hedge funds and other institutional investors own 96.10% of the company’s stock.

ICU Medical Company Profile

ICU Medical, Inc, together with its subsidiaries, develops, manufactures, and sells medical devices used in infusion therapy, vascular access, and vital care applications worldwide. Its infusion therapy products include needlefree products under the MicroClave, MicroClave Clear, and NanoClave brands; Neutron catheter patency devices; ChemoClave and ChemoLock closed system transfer devices, which are used to limit the escape of hazardous drugs or vapor concentrations, block the transfer of environmental contaminants into the system, and eliminates the risk of needlestick injury; Tego needle free connectors; Deltec GRIPPER non-coring needles for portal access; and ClearGuard, SwabCap, and SwabTip disinfection caps.